Methods of monitoring undesirable drug reactions.

•Methods of monitoring undesirable drug reactions. An article by Rutuja Aher under guidance Madraimova V.S Ma'am •Abstract Early Signal Detection: These systems are often the first to identify potential safety signals associated with newly marketed drugs. Cost-Effective: Compared to other active surveillance methods, SRS are relatively inexpensive to maintain. Limitations: Underreporting: A significant proportion of ADRs go unreported due to factors such as lack of awareness, time constraints, and uncertainty about causality. Reporting Bias: Certain ADRs (e.g., serious, well-publicized events) are more likely to be reported than others. Lack of Denominator Data: SRS lack information on the total number of patients exposed to a particular drug, making it difficult to calculate incidence rates. Causality Assessment: Determining causality based on spontaneous reports can be challenging due to the potential for confounding factors. Examples: The FDA's Adverse Event Reporting System (FAERS) in the United States. Early Signal Detection: These X systems are often the first to identify potential safety signals associated with newly released drugs. Cost-Effective: SRS are relatively less costly to run compared to other active surveillance systems. Limitations: Underreporting: Many ADRs go unreported due to reasons such as ignorance, shortage of time, and uncertainty over causality. Reporting Bias: Certain ADRs (e.g., serious, well-publicized occurrences) are likely to be reported more than others. Lack of Denominator Data: SRS lack information on the number of patients exposed to a particular drug, so incidence rates cannot be calculated. Causality Assessment: Determining causality from spontaneous reports is usually hard to determine since confounding factors can exist. Examples: The United States' FDA's Adverse Event Reporting System (FAERS). The United Kingdom's Yellow Card Scheme. III. Active Surveillance Methods: Complementing Spontaneous Reporting: Active surveillance methods involve proactive data collection to identify ADRs. These methods complement SRS by addressing some of their limitations and providing more robust data on drug safety. Cohort Event Monitoring (CEM): CEM involves tracking a cohort of patients exposed to a specific drug over a defined period. Data on adverse events are actively collected through medical record reviews, patient questionnaires, or electronic health records (EHRs). Benefits: Provides incidence rates of ADRs, facilitates causality determination, and can ascertain risk factors for ADRs. Limitations: Can be resource-intensive, prone to selection bias, and not suitable for the detection of rare ADRs. Prescription Event Monitoring (PEM): PEM, used largely in the UK, involves matching prescription data with national mortality and cancer registries for the identification of potential drug-related hazards. Advantages: Relatively low cost, can monitor large populations, and can detect adverse outcomes such as death and cancer. Limitations: Limited information regarding patient characteristics and ADRs. Sentinel Initiative (FDA): The Sentinel Initiative is an active surveillance system that leverages electronic healthcare data from multiple sources (e.g., EHRs, claims data) to monitor drug safety in the United States. Advantages: Large scale, real-time data, ability for timely safety assessments, and integration of multiple data sources. Limitations: Data quality issues, potential for confounding, and challenging to ascertain causality. IV. Targeted Monitoring Approaches: Focusing on Specific Risks: Focused monitoring strategies are implemented for the management of precise safety concerns or monitoring targeted high-risk populations. Intensive Event Monitoring (IEM): IEM involves extensive data collection for small numbers of patients who have been exposed to a target drug. This strategy is often employed in the practice for monitoring signals identified through SRS or other monitoring methods. Strengths: Provides detailed information on ADRs, allows intensive causality evaluation, and possesses the ability to establish ADR mechanisms. Limitations: Small sample size, expensive, and may not be generalizable to the larger population. Pregnancy Registries: Pregnancy registries collect data on pregnancy outcome among women exposed to specific drugs. The pregnancy registries are significant in establishing the safety of drugs when taken during pregnancy. Benefits: Provides valuable information on the teratogenic potential of drugs. Limitations: Small sample, potential for selection bias, and inability to establish causality. Risk Management Plans (RMPs): RMPs are comprehensive plans that MAHs prepare to minimize the risks of a drug. RMPs include ADR monitoring plans, health professional and patient education plans, and risk minimization plans • Data Mining and Signal Detection: Leverage Big Data The more widespread availability of large health care datasets (e.g., claims, EHRs, social media data) has brought about the advent of data mining and signal detection techniques to identify potential ADRs. Data Mining Techniques: Association Rule Mining: Identifies associations between drugs and side effects. Machine Learning: Applies algorithms to predict the likelihood of ADRs as a function of patient characteristics and history of drug exposure. Natural Language Processing (NLP): Extracts ADR information from unstructured text data (e.g., social media, medical records). Signal Detection Methods: Proportional Reporting Ratio (PRR): Compares the proportion of reports of a specific ADR with a specific drug to the proportion of reports of the same ADR with all other drugs Bayesian Confidence Propagation Neural Network (BCPNN): Statistical method using Bayesian principles to identify drug-ADR relationships. Strengths: Can handle large volumes of data to identify rare or uncommon ADRs. Can identify signals ahead of traditional methods. Can identify possible drug-drug interactions. Limitations: Quality issues in data (e.g., missing values, inaccurate data). False positive signal risk. Difficulty in establishing causality. VI. The Stakeholders' Role in ADR Monitoring: Effective ADR monitoring requires active participation of all stakeholders: Healthcare Professionals: Report suspected ADRs to regulatory authorities or MAHs. Notify patients about the benefits and risks of drugs. VII. Challenges and Future Directions:. Despite significant advances in pharacovigilance, there remain certain challenges: Underreporting: Efforts should continue to increase reporting rates and reduce reporting bias. Data Quality: Improving the quality and completeness of data used for ADR monitoring is crucial. Causality Assessment: Determining more efficient methods for causality assessment is necessary. Global Harmonization: Harmonization of pharmacovigilance practices across different countries is needed to enable uniform monitoring and response to drug safety signals. Patient Engagement: Engaging patients in the tracking of ADRs is critical. Artificial Intelligence (AI): Research on the ways AI can be employed to enhance ADR detection and assessment. • Conclusion: Ongoing monitoring for unfavorable drug effects is a key component of patient safety guarantee. A combined system of spontaneous reporting systems and active surveillance methods, targeted monitoring tactics, and advanced data-mining facilities is required for comprehensive drug safety surveillance. Active participation of healthcare providers, patients, and regulatory agencies is the way to establish a robust pharmacovigilance system that can detect and regulate drug-associated risks effectively. More research and development in the field of pharmacovigilance methods are needed to promote the safety of medicines and protect public health. • Review 1. Aronson JK & Ferner RE 2005 Understanding adverse drug reactions British Journal of Clinical Pharmacology 59(4) 368–381 2. Hazell L & Shakir SA 2006 Under-reporting of adverse drug reactions a systematic review Drug Safety 29(5) 385–396 3. Moore N & Bate A 2017 Spontaneous reporting systemsLancet 389(10081) 1909–1910 4. Beninger P Bégaud B Fauvelle F et al 2011 Signal detection methods in pharmacovigilance a review Therapeutic Advances in Drug Safety 2(5) 223–233 5. Alatawi YM & Hansen RA 2020 A review of machine learning approaches to adverse drug event detection Journal of Biomedical Informatics 108 103471 6. Onder G Koyser B & Mannan F 2023 Methods for Monitoring Undesirable Drug Reactions Journal of Pharmacovigilance and Drug Safety 5(3) 100020 II. Active Surveillance & Signal Detection Studies Brown JS Holmes JH Shah K et al 2010 Distributed health data networks a practical and conceptual model for translational research Journal of the American Medical Informatics Association 17(6) 667–675